

Published in final edited form as:

Microcirculation. 2013 April ; 20(3): 239–247. doi:10.1111/micc.12040.

Diversity in Mechanisms of Endothelium-Dependent Vasodilation in Health and Disease

Matthew J. Durand and **David D. Gutterman**

Department of Medicine, Cardiology Division, and Cardiovascular Center, Medical College of Wisconsin, Milwaukee, WI 53226, United States

Abstract

Small arterioles (40–150 μm) contribute to the majority of vascular resistance within organs and tissues. Under resting conditions, the basal tone of these vessels is determined by a delicate balance between vasodilator and vasoconstrictor influences. Cardiovascular homeostasis and regional tissue perfusion is largely a function of the ability of these small blood vessels to constrict or dilate in response to the changing metabolic demands of specific tissues. The endothelial cell layer of these microvessels is a key modulator of vasodilation through the synthesis and release of vasoactive substances. Beyond their vasomotor properties, these compounds importantly modulate vascular cell proliferation, inflammation, and thrombosis. Thus the balance between local regulation of vascular tone and vascular pathophysiology can vary depending upon which factors are released from the endothelium. This review will focus on the dynamic nature of the endothelial released dilator factors depending on species, anatomic site, and presence of disease, with a focus on the human coronary microcirculation. Knowledge how endothelial signaling changes with disease may provide insights into the early stages of developing vascular inflammation and atherosclerosis, or related vascular pathologies.

Introduction

There are a number of vasoactive substances produced by endothelial cells that elicit vasodilation. The prototype is nitric oxide (NO), made by the constitutively expressed enzyme nitric oxide synthase (NOS). NO is synthesized in the endothelial cell layer and signals to underlying vascular smooth muscle cells (VSMCs), where it elicits hyperpolarization and relaxation primarily in a cyclic GMP-dependent manner (Figure 1). A second major family of endothelial derived vasodilator substances are prostaglandins, with the classic example being prostacyclin. Prostaglandins are also constitutively generated by the action of cyclooxygenase (COX) enzymes on arachidonic acid. They traverse the intercellular space and elicit a cAMP-dependent hyperpolarization of VSMCs (Figure 1). The third family of vasoactive substances is generally referred to as endothelial-derived hyperpolarizing factors (EDHFs). EDHFs ultimately cause vasodilation by hyperpolarizing VSMCs via stimulation of K^+ channels or Na^+/K^+ -ATPase. Multiple EDHFs have been described, including hydrogen peroxide (H_2O_2), epoxyeicosatrienoic acids (EETs), carbon monoxide (CO), hydrogen sulfide (H_2S), C-natriuretic peptide (CNP), anandamide, and the potassium ion itself [17].

Studies in animals reveal a rich diversity of vasoactive signaling pathways depending on the vessel size, vascular bed, species, and health of the organism being studied. The purpose of this review is to emphasize the extent of this diversity, focusing on the coronary

Corresponding author: dgutt@mcw.edu.

Disclosures: None

microcirculation where possible (vessels <150 μm in diameter), and highlighting the unique vasomotor plasticity attendant within the human microcirculation in health and disease. While it could be argued that some of the observed diversity among such a large cross-section of studies is dependent on the method of study (for example *in vivo* vs. *in vitro* vessel preparations), it is worth noting that the majority of the studies highlighted in this review use standard cannulated vessel preparations to isolate direct vascular responses in the microvasculature from humoral, neural, and other indirect influences [77].

Diversity and Endothelial Dependent Dilator Mechanisms in Animals

Animal studies have shown that the small coronary arterioles regulate the majority of vascular resistance in the heart [51], therefore modulation of vascular tone in these arterioles is under tight metabolic, myogenic and humoral control [57]. However, the mechanism of endothelium-dependent dilation can vary across species, or even within the same species, depending on the conditions. Consider the stimulus of shear stress produced by an increase in flow through a vessel. The resulting mechanical force activates an endothelium-dependent vasodilation in most vascular beds. Kuo et al. showed that flow-mediated dilation (FMD) in porcine coronary arterioles is completely abolished by inhibiting NOS with L-nitroarginine methyl ester (L-NAME), indicating an exclusive role for NO in this response [40]. Similarly, studies in guinea pig coronary resistance arterioles [80], rat mesenteric arterioles [46], and rat intracerebral arterioles [64] reveal NO as the primary mediator of flow-mediated dilation, while prostaglandins contribute little to the response. Conversely, in small arterioles of the rat cremaster muscle *in vivo*, flow-mediated dilation is primarily mediated by prostaglandins with little role for nitric oxide [38]. However co-release of both nitric oxide and prostaglandins contribute to flow-mediated vasodilation in isolated rat gracilis muscle arterioles [37]. In female endothelial nitric oxide synthase (eNOS) knockout mice, flow-mediated dilation in skeletal muscle arterioles is exclusively mediated by an EDHF (epoxyeicosatrienoic acid) derived from arachidonic acid [29].

Similar to shear stress, a wide range of signaling mechanisms have been reported for agonist-induced vasodilation. For example, adenosine is a potent metabolite dilator of arterioles in multiple vascular beds, however the mechanism is species-specific. Adenosine dilates isolated coronary arterioles from adult pigs [27] and guinea pigs [81] in an endothelium-dependent, NO-mediated manner. Similar responses have also been reported in the conductance coronary vessels of conscious dogs [68]. Conversely, in both main trunk and branch circumflex bovine arterial strips adenosine dilation requires activation of cAMP, suggesting that NO may not play a prominent role in this species at all [78]. Meanwhile, other species show either a partial direct vasodilator effect of adenosine [39, 75], or a vasodilator response that is independent of the endothelium altogether [35, 84].

Bradykinin (BK) is a potent and frequently studied endothelium-dependent dilator of multiple vascular beds, and similar to studies that have examined the mechanisms of adenosine-mediated vasodilation, the mediators of BK-induced dilation are also highly dependent on species and vascular bed. In the cerebral circulation of the rat, BK is a potent NO-dependent vasodilator of isolated middle cerebral arteries [24], but in 3rd order arterioles of the cremaster muscle in the same species, dilation is completely independent of NO [1]. The coronary circulation of different mammalian species also shows a wide diversity of dilator mechanisms to BK. In the rat, dilation is completely independent of NO and prostaglandins, and appears to be mediated by an EDHF derived from a metabolite of arachidonic acid [21, 23], while in the rabbit both NO and prostaglandins play a role [42]. In isolated epicardial right coronary arteries from the porcine coronary circulation, dilation to bradykinin is insensitive to both L-NAME and indomethacin, but is completely abolished in the presence of catalase, indicating a key role for H₂O₂ as the EDHF responsible for BK-

induced vasodilation [52]. This is further supported by a study conducted by Payne et al., which showed that BK-induced vasodilation is significantly reduced in isolated left circumflex coronary arteries of dogs in the presence of TEMPOL, an antioxidant [69].

Mechanism(s) of human microvascular endothelium-dependent dilation

The human microcirculation exhibits developmental patterns of endothelium-dependent dilation similar to those observed in animals, but with several unique differences. In animal models, in infancy, prostaglandins are primarily responsible for acetylcholine-dependent vasodilation (vertebral arteries), while in adult animals the same vascular bed relies on NO as the mediator of acetylcholine-mediated dilation [11]. In humans, plasma concentrations of prostacyclin (PGI₂), the primary endothelium-derived prostaglandin vasodilator, peak at birth and then decrease throughout life [32]. In preliminary studies we have observed that flow-mediated vasodilation in isolated coronary microvessels of infants is exclusively mediated by prostaglandins (cyclooxygenase dependent) [86]. In early adulthood, both NO and prostaglandins contribute, while later in adulthood, NO predominates as the primary factor responsible for FMD [86]. The situation changes dramatically with the onset of disease. For example, in adults with coronary artery disease undergoing bypass surgery, FMD in isolated atrial arterioles is slightly reduced but is NOS- and prostaglandin-independent, being mediated by H₂O₂ as discussed in more detail below [55].

Similar to other mammalian species, diversity exists across human vascular beds in endothelium-dependent dilator responses. In isolated microvessels from subcutaneous adipose tissue, NO and prostaglandins play no role in the dilation to bradykinin, while in visceral adipose arterioles, sensitivity to bradykinin is markedly reduced in the presence of NOS inhibition [76]. Gender and age were also shown to importantly modulate these endothelium-dependent responses [76].

Effect of Genetic Manipulation and Disease on Endothelium- Dependent Dilation

The diversity of endothelium-dependent vasodilator mechanisms present in normal mammalian blood vessels broadens when normal physiology is perturbed with genetic manipulation or disease, revealing a complex compensatory or alternative response system to maintain vasodilation. For example, in wild type mice the vasodilator response to acetylcholine is primarily dependent on NO derived from eNOS in the small coronary arteries [43], while the response to shear is approximately 50% inhibitable by L-NAME [30] in the same vascular bed. Interestingly, in eNOS knockout (KO) mice, the magnitude of the vasodilator response to both acetylcholine and shear stress is no different than in wild type mice [30, 44]. The response remains NO-dependent, however the enzyme responsible for the production of NO shifts to the neuronal isoform of NOS (nNOS), which is normally localized in the intracardiac neurons lining the coronary vessels [34]. Under normal conditions nNOS does not contribute to NO-dependent vasodilation, but with loss of eNOS, the signaling mechanisms in response to both flow and acetylcholine co-opt the nNOS pathway to maintain stimulus-induced NO production and dilation. This artificially induced pathological state is mimicked by pathological states as seen in vessels from spontaneously hypertensive rats [4] and humans with atherosclerosis [85], where significant upregulation of nNOS suggests that a similar compensatory mechanism may be operative.

Vasodilation to bradykinin has also been shown to persist in the coronary circulation of eNOS deficient animals; however the mediator of dilation switches from NO to a CYP450-derived EDHF in the KO animals [14]. While vasodilation has been shown to persist in the eNOS-specific KO mice, it is worth noting that in the double and triple NOS knockout

animals there is progressive loss of acetylcholine-induced dilation as this compensation is lost [59].

It has been widely demonstrated that an association exists between the presence of coronary artery disease (CAD), or its risk factors, and an elevation in vascular superoxide production. Superoxide is a short-lived free-radical, but it reacts 3 times more rapidly with NO to form peroxynitrite than it is dismutated by the superoxide dismutase enzymes, causing a net reduction in the bioavailability of NO [3, 13, 16]. Peroxynitrite and the superoxide anion can also oxidize BH₄ (a critical cofactor of eNOS) to BH₂, uncoupling eNOS so that it no longer produces NO. As with genetic depletion of the eNOS enzyme, disease-induced elevations in superoxide also create an environment where NO bioavailability is reduced [26, 33, 45, 60, 73, 83]. This situation invokes a degree of vasodilator plasticity, much like that observed in knockout mice lacking the eNOS enzyme. This disease-induced compensation is best exemplified in a study by Najibi et al. who examined dilation to acetylcholine in isolated carotid artery segments from hypercholesterolemic rabbits. After 10 weeks of dietary hypercholesterolemia, the sensitivity and magnitude of dilation were identical between the normal and hypercholesterolemic animals [58]. However, the mechanism had changed from one that was primarily mediated by NO-cGMP to one that was instead mediated by an unidentified EDHF. Similarly, Clark and Fuchs reported that the degree of vasodilation to acetylcholine was similar in isolated small coronary arteries from both healthy and cardiomyopathic Gold Syrian hamsters; however the mediator of vasodilation switched from NO in control animals to a cyclooxygenase-derived EDHF in animals with cardiomyopathy [12].

How are these compensatory pathways invoked, often rapidly? One hypothesis to explain these observations is that under normal conditions NO may exert negative feedback to mask these compensatory vasodilator pathways [66]. For this hypothesis to be correct, one would expect exogenous application of NO to have a similar effect. In support of this contention, Nishikawa et al. showed that dilation of canine coronary microvessels to BK is mediated by EDHF *in vivo* when endothelial nitric oxide synthase and cyclooxygenase are inhibited with L-NAME and indomethacin, respectively [66]. In this situation, co-administration of a low, non-dilator dose of the NO donor sodium nitroprusside completely abolished the EDHF-mediated dilation to BK, implicating a role for endogenous NO in inhibiting the compensatory vasodilator pathways under non-disease situations. Similar findings have also been reported in isolated carotid artery segments of rabbits and in porcine coronary arterioles [2]. However not all studies show such a modulating effect of NO [18].

Human microvascular reactivity during stress and disease

As described above, in the presence of CAD, the mechanism of human coronary resistance vessel dilation to shear stress changes from NO to EDHF [54]. Further studies have shown us much about this changed signaling pathway, linking shear stress to mitochondrial production of EDHF. We have also explored the nature of the EDHF involved, and the stimulus activating smooth muscle hyperpolarization.

As demonstrated by bioassay, flow-mediated dilation of isolated human coronary arterioles from patients with CAD elicits release of a transferrable factor that stimulates large conductance calcium-activated potassium channels in the underlying vascular smooth muscle [47]. This factor is hydrogen peroxide, derived from endothelial mitochondria [48, 54]. Interestingly, cytochrome P450 monooxygenase products, likely epoxyeicosatrienoic acids, are also necessary for the flow-mediated dilation [55] but appear not to be the transferrable agent acting on vascular smooth muscle (unpublished observations demonstrating lack of endothelial release of EET in response to shear). In isolated arterioles

from human visceral adipose, a transition is also seen from NO to H₂O₂ as the primary mediator of FMD with the onset of CAD [72]. Thus adipose microvessels might serve as a surrogate for disease-induced changes in coronary vascular reactivity. (Figure 2)

Other disease states may also evoke release of alternative endothelium-mediated dilators in the human microcirculation. In patients with diabetes there is upregulation of COX-2 expression and greater participation by prostaglandins through COX-2 in coronary arteriolar dilation to bradykinin [79]. One of the most striking compensatory responses is observed in isolated mucosal arterioles of patients with inflammatory bowel disease (IBD) [13]. In adjacent unaffected bowel, dilation to acetylcholine is mediated by endothelial release of NO. However in affected tissue, a slightly reduced dilation is seen, but the response is mediated entirely by prostaglandin D₂ through an endothelium-independent mechanism likely involving the underlying smooth muscle [25]. (Figure 2)

Mechanism of endothelium shear signal transduction

How is shear transduced by human coronary endothelial cells to cause mitochondrial production of reactive oxygen species? Recent studies from Zhang's laboratory indicate that lipid raft-bound mechanosensitive transient receptor potential vanilloid 4 (TRPV4) channels are critically involved in human coronary arteriolar FMD [5], and activation of these channels is linked to production of hydrogen peroxide in a mitochondrial-dependent fashion [5].

Alternatively shear may activate calcium entry by other mechanisms. The elevated cell calcium can stimulate phospholipases, cleaving arachidonic acid from cell membranes. Constitutively expressed cytochrome P450 acts on the free arachidonic acid to produce EETs [19]. EETs are known to activate TRPV4 channels and this could explain both their critical role in FMD and their lack of release into the extracellular space [50]. Studies are underway to discern the direct and/or indirect pathways by which shear activates TRPV4 leading to coronary dilation.

Superoxide produced by the mitochondria in response to shear is converted to hydrogen peroxide by MnSOD in the mitochondrial matrix or by CuZn SOD in the intermembrane space. H₂O₂ is freely permeable and can exit both mitochondrial and plasma membranes and enter the underlying smooth muscle cell. There are a variety of ways that H₂O₂ can elicit dilation, including activation of PI3K [9], NOS [15], Kv channels [74], guanylyl cyclase [7] or by opening large conductance calcium-activated potassium (BKca) channels directly [53], or through activation of PKG1 α [6]. In human coronary arterioles the dilation involves activation of PKG1 α , likely through oxidation of the CYS42 residue, forming a disulfide dimer between two molecules of the enzyme [47]. A summary of the proposed signaling pathways responsible for FMD in human coronary arterioles are shown in Figure 3.

Time-Course of Compensatory Dilator Pathways

It is clear that a transition occurs from NO to H₂O₂ as the mediator of human coronary (and adipose) arteriolar dilation in the presence of CAD, but it is not known how rapidly this transition occurs. To examine this question we have subjected healthy individuals to a brief hypertensive stress during isometric exercise [31, 71]. The modest elevation in blood pressure impaired conduit endothelial function (brachial artery flow-mediated dilation) in sedentary subjects [31, 71]. However when athletes were tested, no change in endothelial function was observed. We then extended these findings to the microcirculation using adipose arterioles from gluteal fat pad biopsies of subjects undergoing exercise. Preliminary observations indicate reduced FMD in sedentary subjects following the acute exercise-induced hypertension, however in athletes a different response was observed [70]. FMD in

post-exercise arterioles was similar to that observed in pre-exercise vessels, but the mechanism of dilation had shifted from NO to H₂O₂, similar to that observed in coronary arterioles [70]. These preliminary findings suggest that the transition in mechanism of dilation can occur rapidly, even within an hour, and that the switch in mediators of dilation is similar in athletes and patients with chronic coronary artery disease.

Consequences of Multiple Dilator Pathways

The wide range of vasodilator mechanisms observed in different animal species raises questions about the rationale for the evolutionary diversity of mechanisms of endothelium-dependent dilation. The answers might relate to the non-vasomotor properties of these varied mediators. For example, nitric oxide is a potent inhibitor of platelet and leukocyte adhesion, smooth muscle proliferation and migration, and oxidative stress [20, 28, 49, 61–63]. Therefore, as a common physiological product of healthy endothelial cells, NO is intimately involved in preventing vascular inflammation and atherosclerosis. Decades of research in both animals and humans have shown that risk factors for coronary artery disease up regulate vascular superoxide production, which both quenches and inhibits the production of NO, even though endothelium-dependent dilation may still be present, as has been reported in the rabbit carotid artery [58]. Conversely, vasodilation may be absent as Kuo and colleagues reported in the coronary arterioles of hypercholesterolemic pigs [41], or dilation may persist but be mediated by a different endothelium-derived dilator altogether, such as hydrogen peroxide as seen in arterioles isolated from human adipose tissue [72] or epoxyeicosatrienoic acid as observed in bovine coronary arterioles [10]. It is important to consider that although both H₂O₂ and EETs produce dilation, they have very different effects on atherogenic potential. While EETs share many of the atheroprotective features of NO [65, 82], hydrogen peroxide promotes a pro-inflammatory and pro-atherosclerotic phenotype [8, 22, 56]. It remains to be seen if compensatory H₂O₂-mediated vasodilation, as is observed in the human coronary circulation of patients with CAD [54], acts as a feed-forward mechanism to further promote an atherogenic phenotype.

As described above, this shift in mediator is also observed in preliminary studies in healthy athletes who maintain endothelium-dependent dilation following brief (hypertensive) stress by converting from NO as the endothelial mediator to H₂O₂ [70]. There are several plausible explanations for this transition in endothelial function. Perhaps the ability to continuously maintain endothelium-dependent dilation is of greater importance than the risk of short-term vascular oxidative stress during heightened production of H₂O₂. It is conceivable that the energy required to produce H₂O₂ in a stressed environment is more favorable than the process required to generate NO in such an oxidative environment. H₂O₂ is a more stable mediator of dilation in disease than is NO, because the latter is readily quenched by elevated ambient levels of superoxide. Another explanation is that dismutation of superoxide to H₂O₂ circumvents generation of peroxynitrite, which may be even more detrimental in terms of vascular damage.

It is unclear why such a transition is seen both during health and disease, prompting consideration about the type and duration of stress that is necessary to promote vascular pathology. For example, are there functional differences between short vs. longer term production of H₂O₂ in lieu of NO? There may be lessons learned from other species as well. For example, the pig, which is highly susceptible to coronary artery disease, loses NO as a coronary endothelium released product during hypercholesterolemia [41]. However, the dog, in which induction of coronary plaques is notoriously difficult, has been shown to maintain NO-dependent vasodilation in the coronary arteries when fed a high fat diet [36], and demonstrates a prominent dilation to EETs in the coronary microcirculation under normal conditions [67]. It is worth noting that EETs have an atheroprotective profile similar to NO

[65, 82]. Thus, the consequences of unmasking alternative vasodilator pathways should be considered as potentially harmful rather than as strictly a compensatory “second line of defense” in the vasculature [66].

Summary and Conclusions

The diversity in vasodilator mechanisms across species and vascular beds is striking both in health and disease. Bioavailability of nitric oxide, the prototypical mediator of endothelium-dependent dilation, is highly sensitive to the tissue redox state. It has widely been shown that brief oxidative stress associated with exercise or the chronic stress of disease can switch off NO production. In some cases, such as in the pig coronary arteriole, this results in a loss of endothelium-dependent dilation (to increased shear). However, in others (human coronary and adipose microcirculations) compensatory dilation is unveiled with mitochondrial-derived hydrogen peroxide acting as the principal vasoactive mediator. This has the potential to disrupt the tonic inhibitory endothelial influence on smooth muscle proliferation and vascular inflammation, and may result in a pro-atherosclerotic environment over time. Further investigation is needed to better understand the signaling pathways that are responsible for the shift in mediators of endothelium-dependent dilation. This could lead to new approaches to the prevention and treatment of coronary artery and arteriolar disease.

Acknowledgments

Support was provided by grants from NIH (HL094971 and HL007792).

References

1. Alsip NL, Schuschke DA, Miller FN. Microvascular responses in the skeletal muscle of the diabetic rat. *J Lab Clin Med.* 1996; 128:429–37. [PubMed: 8833893]
2. Bauersachs J, Popp R, Hecker M, Sauer E, Fleming I, Busse R. Nitric oxide attenuates the release of endothelium-derived hyperpolarizing factor. *Circulation.* 1996; 94:3341–7. [PubMed: 8989149]
3. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. *Am J Physiol.* 1996; 271:C1424–C1437. [PubMed: 8944624]
4. Boulanger CM, Heymes C, Benessiano J, Geske RS, Levy BI, Vanhoutte PM. Neuronal nitric oxide synthase is expressed in rat vascular smooth muscle cells: activation by angiotensin II in hypertension. *Circ Res.* 1998; 83:1271–8. [PubMed: 9851944]
5. Bubolz AH, Mendoza SA, Zheng X, Zinkevich NS, Li R, Gutterman DD, Zhang DX. Activation of endothelial TRPV4 channels mediates flow-induced dilation in human coronary arterioles: role of Ca²⁺ entry and mitochondrial ROS signaling. *Am J Physiol Heart Circ Physiol.* 2012; 302:H634–42. [PubMed: 22140047]
6. Burgoyne JR, Madhani M, Cuello F, Charles RL, Brennan JP, Schroder E, Browning DD, Eaton P. Cysteine redox sensor in PKGI α enables oxidant-induced activation. *Science.* 2007; 317:1393–7. [PubMed: 17717153]
7. Burke-Wolin T, Abate CJ, Wolin MS, Gurtner GH. Hydrogen peroxide-induced pulmonary vasodilation: role of guanosine 3',5'-cyclic monophosphate. *Am J Physiol.* 1991; 261:L393–L398. [PubMed: 1662918]
8. Cai H. Hydrogen peroxide regulation of endothelial function: origins, mechanisms, and consequences. *Cardiovasc Res.* 2005; 68:26–36. [PubMed: 16009356]
9. Cai H, Li Z, Davis ME, Kanner W, Harrison DG, Dudley SC Jr. Akt-dependent phosphorylation of serine 1179 and mitogen-activated protein kinase kinase/extracellular signal-regulated kinase 1/2 cooperatively mediate activation of the endothelial nitric-oxide synthase by hydrogen peroxide. *Mol Pharmacol.* 2003; 63:325–31. [PubMed: 12527803]
10. Campbell WB, Falck JR, Gauthier K. Role of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factor in bovine coronary arteries. *Med Sci Monit.* 2001; 7:578–84. [PubMed: 11433180]

11. Charpie JR, Schreur KD, Papadopoulos SM, Webb RC. Endothelium dependency of contractile activity differs in infant and adult vertebral arteries. *J Clin Invest.* 1994; 93:1339–43. [PubMed: 8132776]
12. Clark SG, Fuchs LC. BK(Ca) channels compensate for loss of NOS-dependent coronary artery relaxation in cardiomyopathy. *Am J Physiol Heart Circ Physiol.* 2000; 279:H2598–603. [PubMed: 11087210]
13. Darley-USmar V, Wiseman H, Halliwell B. Nitric oxide and oxygen radicals: a question of balance. *FEBS Lett.* 1995; 369:131–5. [PubMed: 7649244]
14. Ding Z, Godecke A, Schrader J. Contribution of cytochrome P450 metabolites to bradykinin-induced vasodilation in endothelial NO synthase deficient mouse hearts. *Br J Pharmacol.* 2002; 135:631–8. [PubMed: 11834610]
15. Dong DL, Yue P, Yang BF, Wang WH. Hydrogen peroxide stimulates the Ca(2+)-activated big-conductance K channels (BK) through cGMP signaling pathway in cultured human endothelial cells. *Cell Physiol Biochem.* 2008; 22:119–26. [PubMed: 18769038]
16. Faraci FM, Didion SP. Vascular protection: superoxide dismutase isoforms in the vessel wall. *Arterioscler Thromb Vasc Biol.* 2004; 24:1367–73. [PubMed: 15166009]
17. Feletou M, Vanhoutte PM. EDHF: an update. *Clin Sci (Lond).* 2009; 117:139–55. [PubMed: 19601928]
18. Fitzgerald SM, Bashari H, Cox JA, Parkington HC, Evans RG. Contributions of endothelium-derived relaxing factors to control of hindlimb blood flow in the mouse in vivo. *Am J Physiol Heart Circ Physiol.* 2007; 293:H1072–82. [PubMed: 17468338]
19. Fleming I. Cytochrome P450 epoxygenases as EDHF synthase(s). *Pharmacol Res.* 2004; 49:525–33. [PubMed: 15026030]
20. Forstermann U. Nitric oxide and oxidative stress in vascular disease. *Pflügers Arch.* 2010; 459:923–39. [PubMed: 20306272]
21. Fulton D, Mahboubi K, McGiff JC, Quilley J. Cytochrome P450-dependent effects of bradykinin in the rat heart. *Br J Pharmacol.* 1995; 114:99–102. [PubMed: 7712035]
22. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. *J Clin Invest.* 1989; 83:1774–7. [PubMed: 2540223]
23. Given MB, Greenberg SS, Giles TD. Coronary vasodilator responses to bradykinin in euglycemic and diabetic rats. *Am J Hypertens.* 2001; 14:446–54. [PubMed: 11368466]
24. Gorchach C, Wahl M. Bradykinin dilates rat middle cerebral artery and its large branches via endothelial B2 receptors and release of nitric oxide. *Peptides.* 1996; 17:1373–8. [PubMed: 8971934]
25. Hatoum OA, Gauthier KM, Binion DG, Miura H, Telford G, Otterson MF, Campbell WB, Gutterman DD. Novel mechanism of vasodilation in inflammatory bowel disease. *Arterioscler Thromb Vasc Biol.* 2005; 25:2355–61. [PubMed: 16141408]
26. Hattori Y, Kawasaki H, Abe K, Kanno M. Superoxide dismutase recovers altered endothelium-dependent relaxation in diabetic rat aorta. *Am J Physiol.* 1991; 261:H1086–94. [PubMed: 1928390]
27. Hein TW, Kuo L. cAMP-independent dilation of coronary arterioles to adenosine : role of nitric oxide, G proteins, and K(ATP) channels. *Circ Res.* 1999; 85:634–42. [PubMed: 10506488]
28. Hossain M, Qadri SM, Liu L. Inhibition of nitric oxide synthesis enhances leukocyte rolling and adhesion in human microvasculature. *J Inflamm (Lond).* 2012; 9:28. [PubMed: 22812684]
29. Huang A, Sun D, Carroll MA, Jiang H, Smith CJ, Connetta JA, Falck JR, Shesely EG, Koller A, Kaley G. EDHF mediates flow-induced dilation in skeletal muscle arterioles of female eNOS-KO mice. *Am J Physiol Heart Circ Physiol.* 2001; 280:H2462–9. [PubMed: 11356599]
30. Huang A, Sun D, Shesely EG, Levee EM, Koller A, Kaley G. Neuronal NOS- dependent dilation to flow in coronary arteries of male eNOS-KO mice. *Am J Physiol Heart Circ Physiol.* 2002; 282:H429–36. [PubMed: 11788389]
31. Jurva JW, Phillips SA, Syed AQ, Syed AY, Pitt S, Weaver A, Gutterman DD. The effect of exertional hypertension evoked by weight lifting on vascular endothelial function. *J Am Coll Cardiol.* 2006; 48:588–9. [PubMed: 16875990]

32. Kaapa P, Viinikka L, Ylikorkala O. Plasma prostacyclin from birth to adolescence. *Arch Dis Child.* 1982; 57:459–61. [PubMed: 7046649]
33. Keaney JF Jr, Xu A, Cunningham D, Jackson T, Frei B, Vita JA. Dietary probucol preserves endothelial function in cholesterol-fed rabbits by limiting vascular oxidative stress and superoxide generation. *J Clin Invest.* 1995; 95:2520–9. [PubMed: 7769097]
34. Kelly RA, Balligand JL, Smith TW. Nitric oxide and cardiac function. *Circ Res.* 1996; 79:363–80. [PubMed: 8781470]
35. King AD, Milavec-Krizman M, Muller-Schweinitzer E. Characterization of the adenosine receptor in porcine coronary arteries. *Br J Pharmacol.* 1990; 100:483–6. [PubMed: 2390673]
36. Knudson JD, Dincer UD, Dick GM, Shibata H, Akahane R, Saito M, Tune JD. Leptin resistance extends to the coronary vasculature in prediabetic dogs and provides a protective adaptation against endothelial dysfunction. *Am J Physiol Heart Circ Physiol.* 2005; 289:H1038–46. [PubMed: 15894577]
37. Koller A, Huang A, Sun D, Kaley G. Exercise training augments flow-dependent dilation in rat skeletal muscle arterioles. Role of endothelial nitric oxide and prostaglandins. *Circ Res.* 1995; 76:544–50. [PubMed: 7534658]
38. Koller A, Kaley G. Prostaglandins mediate arteriolar dilation to increased blood flow velocity in skeletal muscle microcirculation. *Circ Res.* 1990; 67:529–34. [PubMed: 2115825]
39. Kuo L, Chancellor JD. Adenosine potentiates flow-induced dilation of coronary arterioles by activating KATP channels in endothelium. *Am J Physiol.* 1995; 269:H541–9. [PubMed: 7653618]
40. Kuo L, Chilian WM, Davis MJ. Interaction of pressure- and flow-induced responses in porcine coronary resistance vessels. *Am J Physiol.* 1991; 261:H1706–15. [PubMed: 1750529]
41. Kuo L, Davis MJ, Cannon MS, Chilian WM. Pathophysiological consequences of atherosclerosis extend into the coronary microcirculation. Restoration of endothelium-dependent responses by L-arginine. *Circ Res.* 1992; 70:465–76. [PubMed: 1537085]
42. Lamontagne D, Konig A, Bassenge E, Busse R. Prostacyclin and nitric oxide contribute to the vasodilator action of acetylcholine and bradykinin in the intact rabbit coronary bed. *J Cardiovasc Pharmacol.* 1992; 20:652–7. [PubMed: 1280723]
43. Lamping KG, Nuno DW, Chappell DA, Faraci FM. Agonist-specific impairment of coronary vascular function in genetically altered, hyperlipidemic mice. *Am J Physiol.* 1999; 276:R1023–9. [PubMed: 10198381]
44. Lamping KG, Nuno DW, Shesely EG, Maeda N, Faraci FM. Vasodilator mechanisms in the coronary circulation of endothelial nitric oxide synthase-deficient mice. *Am J Physiol Heart Circ Physiol.* 2000; 279:H1906–12. [PubMed: 11009479]
45. Laursen JB, Rajagopalan S, Galis Z, Tarpey M, Freeman BA, Harrison DG. Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. *Circulation.* 1997; 95:588–93. [PubMed: 9024144]
46. Learmont JG, Cockell AP, Knock GA, Poston L. Myogenic and flow-mediated responses in isolated mesenteric small arteries from pregnant and nonpregnant rats. *Am J Obstet Gynecol.* 1996; 174:1631–6. [PubMed: 9065143]
47. Liu Y, Bubolz AH, Mendoza S, Zhang DX, Gutterman DD. H₂O₂ is the transferrable factor mediating flow-induced dilation in human coronary arterioles. *Circ Res.* 2011; 108:566–73. [PubMed: 21233456]
48. Liu Y, Zhao H, Li H, Kalyanaraman B, Nicolosi AC, Gutterman DD. Mitochondrial sources of H₂O₂ generation play a key role in flow-mediated dilation in human coronary resistance arteries. *Circ Res.* 2003; 93:573–80. [PubMed: 12919951]
49. Lloyd-Jones DM, Bloch KD. The vascular biology of nitric oxide and its role in atherogenesis. *Annu Rev Med.* 1996; 47:365–75. [PubMed: 8712788]
50. Loot AE, Popp R, Fisslthaler B, Vriens J, Nilius B, Fleming I. Role of cytochrome P450-dependent transient receptor potential V4 activation in flow-induced vasodilatation. *Cardiovasc Res.* 2008; 80:445–52. [PubMed: 18682435]
51. Marcus ML, Chilian WM, Kanatsuka H, Dellsperger KC, Eastham CL, Lamping KG. Understanding the coronary circulation through studies at the microvascular level. *Circulation.* 1990; 82:1–7. [PubMed: 2114232]

52. Matoba T, Shimokawa H, Morikawa K, Kubota H, Kunihiro I, Urakami-Harasawa L, Mukai Y, Hirakawa Y, Akaike T, Takeshita A. Electron spin resonance detection of hydrogen peroxide as an endothelium-derived hyperpolarizing factor in porcine coronary microvessels. *Arterioscler Thromb Vasc Biol.* 2003; 23:1224–30. [PubMed: 12763764]
53. Matoba T, Shimokawa H, Nakashima M, Hirakawa Y, Mukai Y, Hirano K, Kanaide H, Takeshita A. Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in mice. *J Clin Invest.* 2000; 106:1521–30. [PubMed: 11120759]
54. Miura H, Bosnjak JJ, Ning G, Saito T, Miura M, Gutterman DD. Role for hydrogen peroxide in flow-induced dilation of human coronary arterioles. *Circ Res.* 2003; 92:e31–40. [PubMed: 12574154]
55. Miura H, Wachtel RE, Liu Y, Loberiza FR Jr, Saito T, Miura M, Gutterman DD. Flow-induced dilation of human coronary arterioles: important role of Ca(2+)-activated K(+) channels. *Circulation.* 2001; 103:1992–8. [PubMed: 11306529]
56. Mooradian DL, Hutsell TC, Keefer LK. Nitric oxide (NO) donor molecules: effect of NO release rate on vascular smooth muscle cell proliferation in vitro. *J Cardiovasc Pharmacol.* 1995; 25:674–8. [PubMed: 7596138]
57. Muller JM, Davis MJ, Chilian WM. Integrated regulation of pressure and flow in the coronary microcirculation. *Cardiovasc Res.* 1996; 32:668–78. [PubMed: 8915185]
58. Najibi S, Cowan CL, Palacino JJ, Cohen RA. Enhanced role of potassium channels in relaxations to acetylcholine in hypercholesterolemic rabbit carotid artery. *Am J Physiol.* 1994; 266:H2061–7. [PubMed: 7515589]
59. Nakata S, Tsutsui M, Shimokawa H, Suda O, Morishita T, Shibata K, Yatera Y, Sabanai K, Tanimoto A, Nagasaki M, Tasaki H, Sasaguri Y, Nakashima Y, Otsuji Y, Yanagihara N. Spontaneous myocardial infarction in mice lacking all nitric oxide synthase isoforms. *Circulation.* 2008; 117:2211–23. [PubMed: 18413498]
60. Nakazono K, Watanabe N, Matsuno K, Sasaki J, Sato T, Inoue M. Does superoxide underlie the pathogenesis of hypertension? *Proc Natl Acad Sci U S A.* 1991; 88:10045–8. [PubMed: 1658794]
61. Newby AC, Fabunmi RP, George SJ, Southgate KM, Banning AP, Thurston VJ, Williams A. Neointimal fibrosis in vascular pathologies: role of growth factors and metalloproteinases in vascular smooth muscle proliferation. *Exp Nephrol.* 1995; 3:108–13. [PubMed: 7773629]
62. Newby AC, George SJ. Proliferation, migration, matrix turnover, and death of smooth muscle cells in native coronary and vein graft atherosclerosis. *Curr Opin Cardiol.* 1996; 11:574–82. [PubMed: 8968671]
63. Newby AC, Zaltsman AB. Fibrous cap formation or destruction—the critical importance of vascular smooth muscle cell proliferation, migration and matrix formation. *Cardiovasc Res.* 1999; 41:345–60. [PubMed: 10341834]
64. Ngai AC, Winn HR. Modulation of cerebral arteriolar diameter by intraluminal flow and pressure. *Circ Res.* 1995; 77:832–40. [PubMed: 7554130]
65. Ni GH, Chen JF, Chen XP, Yang TL. Soluble epoxide hydrolase: a promising therapeutic target for cardiovascular diseases. *Pharmazie.* 2011; 66:153–7. [PubMed: 21553642]
66. Nishikawa Y, Stepp DW, Chilian WM. Nitric oxide exerts feedback inhibition on EDHF-induced coronary arteriolar dilation in vivo. *Am J Physiol Heart Circ Physiol.* 2000; 279:H459–65. [PubMed: 10924042]
67. Oltman CL, Weintraub NL, VanRollins M, Dellsperger KC. Epoxyeicosatrienoic acids and dihydroxyeicosatrienoic acids are potent vasodilators in the canine coronary microcirculation. *Circ Res.* 1998; 83:932–9. [PubMed: 9797342]
68. Parent R, Pare R, Lavalley M. Contribution of nitric oxide to dilation of resistance coronary vessels in conscious dogs. *Am J Physiol.* 1992; 262:H10–6. [PubMed: 1733302]
69. Payne GA, Borbouse L, Bratz IN, Roell WC, Bohlen HG, Dick GM, Tune JD. Endogenous adipose-derived factors diminish coronary endothelial function via inhibition of nitric oxide synthase. *Microcirculation.* 2008; 15:417–26. [PubMed: 18574744]
70. Phillips SA, Bian JT, Church EC, Das EK, Vidovich M, Gutterman DD. Hydrogen Peroxide Prevents Impaired Endothelium-dependent Dilation Following Acute Exertion in Chronic Exercising but Not in Sedentary Subjects. *Circulation.* 2009; 120:S1013. (Abstract).

71. Phillips SA, Das E, Wang J, Pritchard K, Gutterman DD. Resistance and aerobic exercise protects against acute endothelial impairment induced by a single exposure to hypertension during exertion. *J Appl Physiol*. 2011; 110:1013–20. [PubMed: 21252216]
72. Phillips SA, Hatoum OA, Gutterman DD. The mechanism of flow-induced dilation in human adipose arterioles involves hydrogen peroxide during CAD. *Am J Physiol Heart Circ Physiol*. 2007; 292:H93–100. [PubMed: 17040967]
73. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. *J Clin Invest*. 1996; 97:1916–23. [PubMed: 8621776]
74. Rogers PA, Chilian WM, Bratz IN, Bryan RM Jr, Dick GM. H₂O₂ activates redox- and 4-aminopyridine-sensitive K_v channels in coronary vascular smooth muscle. *Am J Physiol Heart Circ Physiol*. 2007; 292:H1404–11. [PubMed: 17071731]
75. Rubanyi G, Vanhoutte PM. Endothelium-removal decreases relaxations of canine coronary arteries caused by beta-adrenergic agonists and adenosine. *J Cardiovasc Pharmacol*. 1985; 7:139–44. [PubMed: 2580134]
76. Sato A, Miura H, Liu Y, Somberg LB, Otterson MF, Demeure MJ, Schulte WJ, Eberhardt LM, Loberiza FR, Sakuma I, Gutterman DD. Effect of gender on endothelium-dependent dilation to bradykinin in human adipose microvessels. *Am J Physiol Heart Circ Physiol*. 2002; 283:H845–52. [PubMed: 12181110]
77. Siegl D, Koeppen M, Wolffe SE, Pohl U, de Wit C. Myoendothelial coupling is not prominent in arterioles within the mouse cremaster microcirculation in vivo. *Circ Res*. 2005; 97:781–8. [PubMed: 16166558]
78. Silver PJ, Walus K, DiSalvo J. Adenosine-mediated relaxation and activation of cyclic AMP-dependent protein kinase in coronary arterial smooth muscle. *J Pharmacol Exp Ther*. 1984; 228:342–7. [PubMed: 6694113]
79. Szerafin T, Erdei N, Fulop T, Pasztor ET, Edes I, Koller A, Bagi Z. Increased cyclooxygenase-2 expression and prostaglandin-mediated dilation in coronary arterioles of patients with diabetes mellitus. *Circ Res*. 2006; 99:e12–7. [PubMed: 16917094]
80. Ueeda M, Silvia SK, Olsson RA. Nitric oxide modulates coronary autoregulation in the guinea pig. *Circ Res*. 1992; 70:1296–303. [PubMed: 1374299]
81. Vials A, Burnstock G. A₂-purinoceptor-mediated relaxation in the guinea-pig coronary vasculature: a role for nitric oxide. *Br J Pharmacol*. 1993; 109:424–9. [PubMed: 8358543]
82. Wang YX, Ulu A, Zhang LN, Hammock B. Soluble epoxide hydrolase in atherosclerosis. *Curr Atheroscler Rep*. 2010; 12:174–83. [PubMed: 20425256]
83. White CR, Brock TA, Chang LY, Crapo J, Briscoe P, Ku D, Bradley WA, Gianturco SH, Gore J, Freeman BA, et al. Superoxide and peroxynitrite in atherosclerosis. *Proc Natl Acad Sci U S A*. 1994; 91:1044–8. [PubMed: 8302829]
84. White TD, Angus JA. Relaxant effects of ATP and adenosine on canine large and small coronary arteries in vitro. *Eur J Pharmacol*. 1987; 143:119–26. [PubMed: 3691646]
85. Wilcox JN, Subramanian RR, Sundell CL, Tracey WR, Pollock JS, Harrison DG, Marsden PA. Expression of multiple isoforms of nitric oxide synthase in normal and atherosclerotic vessels. *Arterioscler Thromb Vasc Biol*. 1997; 17:2479–88. [PubMed: 9409218]
86. Zinkevich N, Wittenburg A, Gutterman DD. Role Of Cyclooxygenase In Flow-induced Dilation Of Human Coronary Arterioles Depends Upon Age. *Circulation*. 2010; 122:A15764. (Abstract).




Figure 1. Traditional endothelium-dependent mediators of vasodilation in the microcirculation. Agonists such as bradykinin (BK) and acetylcholine (Ach), or mechanical forces such as shear stress, increase vessel diameter in an endothelium-dependent manner by stimulating production of nitric oxide, or release of arachidonic acid which then is metabolized to prostacyclin or epoxyeicosatrienoic acids. These substances move to the underlying vascular smooth muscle to elicit relaxation through cGMP, cAMP, and/or membrane hyperpolarization, respectively. AA (arachidonic acid); AC (adenylyl cyclase); ATP (adenosine triphosphate); cAMP (cyclic adenosine monophosphate); cGMP (cyclic guanosine monophosphate); COX (cyclooxygenase); CYP450(cytochrome P450 monooxygenase); EDHF (endothelium derived hyperpolarizing factor); EET (epoxyeicosatrienoic acid); GC (guanylyl cyclase); GTP (guanosine triphosphate); Kca (large conductance calcium-activated potassium channel); L-arg (L-arginine); NO (nitric oxide); NOS (nitric oxide synthase); PGI2 (prostacyclin); PLC (phospholipase).




Figure 2. Diversity in endothelium- dependent dilator pathways in the human microcirculation. Depending on the stimulus/agonist applied and the vessel origin, a variety of pathway mediators, including NO, prostanoids, reactive oxygen species, and cytochrome P450 metabolites, contribute to endothelium-dependent dilation. Abbreviations similar to Figure 1. CAD (coronary artery disease); DM (diabetes); H₂O₂ (hydrogen peroxide); HCA (human coronary arterioles); IBD (inflammatory bowel disease); Nl (normal); PG (prostaglandin); PGD₂ (prostaglandin D₂); SOD (superoxide dismutase).




Figure 3.

Schematic depiction of mechanochemical signaling pathway responsible for flow-mediated dilation in human coronary arterioles. Shear stress can activate phospholipases to cleave arachidonic acid from cell membranes. This serves as a substrate for CYP450 monooxygenase production of EETs. These metabolites and/or shear directly activate TRPV4 channels to enhance calcium entry into endothelial cells. The rise in calcium, together with enhanced production of ROS from NADPH oxidase and mechanosensitive factors (unpublished data), stimulates mitochondrial production of superoxide. The mitochondrial-produced superoxide is dismutated to hydrogen peroxide, which diffuses to the vascular smooth muscle cell layer to oxidize cysteine residues of PKG1 α , causing homodimerization and activation of the enzyme. The activated dimer opens BK channels on the cell membrane, leading to hyperpolarization and relaxation of the vascular smooth muscle layer. Abbreviations similar to Figure 1. Also: CuZn SOD (copper-zinc superoxide dismutase); MnSOD (Manganese superoxide dismutase); PKG1 α (protein kinase G 1 α); PLA₂ (phospholipase A₂); TRPV4 (transient receptor potential vanilloid 4).